Angiodynamics (ANGO) closed at $11.73 on November 6, 2026, down 0.7% from the previous close, on volume of 339,400 shares (30-day average 888,245).
Data as of November 6, 2026.
6-Nov-2026
AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 6-Nov 6:00 PM ET)
AngioDynamics to Participate in Upcoming Investor Conferences
Business Wire (Thu, 29-Oct 8:00 AM ET)
Business Wire (Wed, 21-Oct 8:30 AM ET)
Business Wire (Wed, 14-Oct 7:00 AM ET)
Business Wire (Thu, 8-Oct 6:02 AM ET)
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
Business Wire (Thu, 8-Oct 6:00 AM ET)
Business Wire (Fri, 2-Oct 6:00 AM ET)
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
Business Wire (Tue, 29-Sep 8:07 AM ET)
AngioDynamics Achieves Record Med Tech Growth and Expands Profitability in Fiscal 2026
Market Chameleon (Wed, 15-Jul 7:44 AM ET)
ANGO Stock Slides 12.2% After Earnings: Does History Suggest More Downside Ahead?
Market Chameleon (Tue, 6-Jan 6:11 AM ET)
AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.
Angiodynamics trades on the NASDAQ stock market under the symbol ANGO.
As of November 6, 2026, ANGO stock price declined to $11.73 with 339,400 million shares trading.
ANGO has a beta of -0.28, meaning it tends to be less sensitive to market movements. ANGO has a correlation of 0.01 to the broad based SPY ETF.
ANGO has a market cap of $493.30 million. This is considered a Small Cap stock.
Last quarter Angiodynamics reported $81 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $327,000 and exceeded earnings estimates by $.07.
In the last 3 years, ANGO traded as high as $16.29 and as low as $5.26.
The top ETF exchange traded funds that ANGO belongs to (by Net Assets): VTI, IWM, VXF, DFAS, VTWO.
ANGO has underperformed the market in the last year with a price return of 0.0% while the SPY ETF gained +10.8%. ANGO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.4% and -5.1%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
ANGO support price is $11.40 and resistance is $12.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANGO shares will trade within this expected range on the day.